Fabry Australia is thrilled to read the announcement on listing Galafold® (migalastat)


Fabry Australia is thrilled to read the announcement on listing Galafold® (migalastat) to treat patients diagnosed with Fabry Disease on the Life Saving Drugs Program on Thursday 1st of November. This listing announcement means the Australian Fabry patient community with amenable mutations now have treatment choice when speaking to their doctors about how to best manage the debilitating effects of their disease. To read the full story Press Here


105 views